Rationale, design and critical end points for the Riluzole in Acute Spinal Cord Injury Study (RISCIS): a randomized, double-blinded, placebo-controlled parallel multi-center trial

BACKGROUND: Riluzole is a sodium channel-blocking agent used in treating amyotrophic lateral sclerosis. It has been approved by the U.S. Food and Drug Administration, Canadian and Australian authorities, and in many other countries. A phase I trial of riluzole for acute spinal cord injury (SCI) prov...

Descripción completa

Detalles Bibliográficos
Autores principales: Fehlings, M G, Nakashima, H, Nagoshi, N, Chow, D S L, Grossman, R G, Kopjar, B
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2016
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5399137/
https://www.ncbi.nlm.nih.gov/pubmed/26099215
http://dx.doi.org/10.1038/sc.2015.95

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5399137/
https://www.ncbi.nlm.nih.gov/pubmed/26099215
http://dx.doi.org/10.1038/sc.2015.95

Ejemplares similares